骨闪烁扫描期间胎儿所接受的吸收剂量。

Absorbed dose to the fetus during bone scintigraphy.

作者信息

Hedrick W R, DiSimone R N, Wolf B H, Langer A

机构信息

Department of Radiology, Aultman Hospital, Canton, OH 44710.

出版信息

Radiology. 1988 Jul;168(1):245-8. doi: 10.1148/radiology.168.1.3380967.

DOI:10.1148/radiology.168.1.3380967

PMID:3380967

Abstract

The authors observed the uptake of radiopharmaceutical and calculated absorbed dose in fetuses of two patients who underwent bone scintigraphy with technetium-99m methylene diphosphonate. Dose estimates per administered activity were 17 mrad/mCi (4.6 microGy/MBq) for an 8-week-old fetus and 9.7 mrad/mCi (2.6 microGy/MBq) for an 18-week-old fetus. Neither fetus demonstrated radionuclide uptake above maternal background levels. The uterine activity showed rapid clearance, with an effective half-life of 12 minutes after reaching a maximum within 1 minute after injection. Major contribution to fetal dose comes from the presence of the radionuclide in the maternal bladder. The authors conclude that bone scintigraphy performed unknowingly in pregnant individuals presents negligible increased risk to the fetus.

摘要

作者观察了两名接受锝-99m亚甲基二膦酸盐骨闪烁显像的患者胎儿对放射性药物的摄取情况，并计算了吸收剂量。每给予单位活度的剂量估计值，8周龄胎儿为17毫拉德/毫居里（4.6微戈瑞/兆贝可），18周龄胎儿为9.7毫拉德/毫居里（2.6微戈瑞/兆贝可）。两个胎儿均未显示出放射性核素摄取高于母体本底水平。子宫内的放射性活度显示出快速清除，在注射后1分钟内达到最大值后，有效半衰期为12分钟。胎儿剂量的主要来源是母体膀胱中放射性核素的存在。作者得出结论，在未意识到怀孕的个体中进行骨闪烁显像对胎儿造成的风险增加可忽略不计。